SIRT3 and hydrops fetalis: As mentioned above, these findings demonstrate that 2-APQC is a targeted SIRT3 activator as a a promising potential drug candidate that alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis for the future HF therapeutics.